NCT05667727View on ClinicalTrials.gov

The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions

Shortness of BreathAsthma in ChildrenEpinephrine Causing Adverse Effects in Therapeutic UseSalbutamol Adverse Reaction

Interventions

DRUG

nebulized epinephrine

we are using 1:1000 epinephrine into nebulization form

DRUG

Salbutamol

Patient will receive salbutamol as 4th nebulization.

Trial Locations (1)

Unknown

Royal Hospital, Muscat

All Listed Sponsors

lead

Oman Medical Speciality Board

OTHER_GOV

NCT05667727 - The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome | Biotech Hunter | Biotech Hunter